Gentian Diagnostics ASA – OSE:GENT.OL
Gentian Diagnostics ASA stock price today
Gentian Diagnostics ASA stock price monthly change
Gentian Diagnostics ASA stock price quarterly change
Gentian Diagnostics ASA stock price yearly change
Gentian Diagnostics ASA key metrics
Market Cap | 755.69M |
Enterprise value | 522.76M |
P/E | -25.42 |
EV/Sales | 5.47 |
EV/EBITDA | -28.97 |
Price/Sales | 6.28 |
Price/Book | 3.80 |
PEG ratio | 0.59 |
EPS | -0.35 |
Revenue | 143.11M |
EBITDA | 12.43M |
Income | -5.54M |
Revenue Q/Q | 22.47% |
Revenue Y/Y | 27.19% |
Profit margin | -29.93% |
Oper. margin | -29.84% |
Gross margin | 48.31% |
EBIT margin | -29.84% |
EBITDA margin | 8.69% |
create your own Smart Feed
Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.
Sign up for freeGentian Diagnostics ASA stock price history
Gentian Diagnostics ASA stock forecast
Gentian Diagnostics ASA financial statements
| Jun 2023 | 34.17M | 908K | 2.66% |
|---|---|---|---|
| Sep 2023 | 32.96M | -816K | -2.48% |
| Dec 2023 | 37.46M | -9.79M | -26.13% |
| Mar 2024 | 38.50M | 4.15M | 10.8% |
| 2025 | 226M | 13.57M | 6.01% |
|---|---|---|---|
| 2026 | 352.4M | 0 |
Analysts Price target
Financials & Ratios estimates
| Jun 2023 | 190403000 | 34.64M | 18.2% |
|---|---|---|---|
| Sep 2023 | 188046000 | 32.37M | 17.22% |
| Dec 2023 | 180587000 | 33.65M | 18.64% |
| Mar 2024 | 186586000 | 35.17M | 18.85% |
| Jun 2023 | 7.08M | -1.11M | -1.17M |
|---|---|---|---|
| Sep 2023 | -2.03M | -1.15M | -1.11M |
| Dec 2023 | 13.68M | -1.54M | -1.15M |
| Mar 2024 | 2.56M | -3.18M | -1.22M |
Gentian Diagnostics ASA alternative data
| Aug 2023 | 55 |
|---|---|
| Sep 2023 | 55 |
| Oct 2023 | 55 |
| Nov 2023 | 55 |
| Dec 2023 | 55 |
| Jan 2024 | 55 |
| Feb 2024 | 55 |
| Mar 2024 | 58 |
| Apr 2024 | 58 |
| May 2024 | 58 |
| Jun 2024 | 58 |
| Jul 2024 | 58 |
Gentian Diagnostics ASA other data
-
What's the price of Gentian Diagnostics ASA stock today?
One share of Gentian Diagnostics ASA stock can currently be purchased for approximately $41.9.
-
When is Gentian Diagnostics ASA's next earnings date?
Unfortunately, Gentian Diagnostics ASA's (GENT.OL) next earnings date is currently unknown.
-
Does Gentian Diagnostics ASA pay dividends?
No, Gentian Diagnostics ASA does not pay dividends.
-
How much money does Gentian Diagnostics ASA make?
Gentian Diagnostics ASA has a market capitalization of 755.69M and it's past years’ income statements indicate that its last revenue has increased compared to the previous period by 34% to 136.19M US dollars.
-
What is Gentian Diagnostics ASA's stock symbol?
Gentian Diagnostics ASA is traded on the OSE under the ticker symbol "GENT.OL".
-
What is Gentian Diagnostics ASA's primary industry?
Company operates in the Healthcare sector and Medical Devices industry.
-
How do i buy shares of Gentian Diagnostics ASA?
Shares of Gentian Diagnostics ASA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
-
How many employees does Gentian Diagnostics ASA have?
As Jul 2024, Gentian Diagnostics ASA employs 58 workers.
-
When Gentian Diagnostics ASA went public?
Gentian Diagnostics ASA is publicly traded company for more then 8 years since IPO on 14 Dec 2016.
-
What is Gentian Diagnostics ASA's official website?
The official website for Gentian Diagnostics ASA is gentian.com.
-
How can i contact Gentian Diagnostics ASA?
Gentian Diagnostics ASA can be reached via phone at +47 993 39 905.
Gentian Diagnostics ASA company profile:
Gentian Diagnostics ASA
gentian.comOSE
55
Medical Devices
Healthcare
Gentian Diagnostics ASA researches, develops, and produces biochemical reagents for use in medical diagnostics and research in Europe, Asia, and the United States. It offers in-vitro diagnostic reagents for clinical chemistry analyzers. The company's products include the gentian calprotectin immunoassay, a turbidimetric assay used for the measurement of calprotectin in plasma and serum for detection and assessment of inflammation; Cystatin C, a superior GFR marker for the diagnosis and therapeutic control of renal function; NT-proBNP Immunoassay for diagnosis, monitoring, and assessment of severity in individuals suspected of having congestive heart failure; and Canine c-reactive protein (CRP) immunoassay, a particle-enhanced turbidimetric immunoassay for quantitative determination of canine CRP in dog plasma and serum. It also provides turbidimetric SARS-CoV-2 total antibody immunoassay, a quantitative antibody test for detecting antibodies targeting the S1-subunit. The company was incorporated in 2001 and is headquartered in Moss, Norway.
Moss, 1596
:
:
:
